In addition, breast cancer patients have participated in clinical trials analyzing sabatolimab (MBG453, anti-TIM-3 mAb) as a single agent or in combination with spartalizumab (anti-PD-1 mAb) [73]. Here, HAVCR2 is linked to breast carcinoma.